Androgen Receptors (Androgen Receptor)

Subscribe to Selected New Research on Androgen Receptors

3569 relevant articles (50 outcomes, 375 trials/studies) found for this Bio-Agent

Description: Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA.

Also Known As:

Androgen Receptor; Receptors, Androgen; 5 alpha-Dihydrotestosterone Receptor; Dihydrotestosterone Receptors; Receptor, Testosterone; Receptors, Androgens; Receptors, Dihydrotestosterone; Receptors, Stanolone; Stanolone Receptor; Testosterone Receptor; 5 alpha Dihydrotestosterone Receptor; Androgens Receptors; Receptor, 5 alpha-Dihydrotestosterone; Receptor, Androgen; Receptor, Stanolone; Stanolone Receptors; alpha-Dihydrotestosterone Receptor, 5

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 58433

Transcription Factors: 10777

Steroid Receptors: 1476

Androgen Receptors: 3569

etiocholanolone receptor: 1

human AR protein: 1

5 alpha-androst-16-en-3-one receptor

androstane-3,17-diol receptor

Cytoplasmic and Nuclear Receptors: 553

Steroid Receptors: 1476

Androgen Receptors: 3569

etiocholanolone receptor: 1

human AR protein: 1

5 alpha-androst-16-en-3-one receptor

androstane-3,17-diol receptor

Experts

1.	Chang, Chawnshang: 33 articles (09/2008 - 02/2002)
2.	Yeh, Shuyuan: 19 articles (09/2008 - 02/2002)
3.	Miyamoto, Hiroshi: 11 articles (09/2008 - 02/2002)
4.	Culig, Zoran: 11 articles (06/2008 - 11/2002)
5.	Bartsch, Georg: 11 articles (03/2006 - 02/2002)
6.	Altuwaijri, Saleh: 10 articles (09/2008 - 09/2002)
7.	Tindall, Donald J: 10 articles (07/2008 - 01/2002)
8.	Young, Charles Y F: 10 articles (06/2008 - 07/2003)
9.	Tilley, Wayne D: 10 articles (06/2008 - 09/2004)
10.	Bonaccorsi, Lorella: 9 articles (10/2008 - 12/2002)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 07/01/2006 - "Based on our in vivo model, androgen is beneficial for the treatment of androgen-independent androgen receptor-rich prostate cancer and modulation of LXR signaling may be a potentially useful therapy for prostate cancer." 01/01/1996 - "The observation, therefore, that antiandrogen withdrawal can be beneficial for some prostate cancer patients, might be understood in the light of an altered ligand responsiveness of mutant androgen receptors." 04/15/2007 - "In vitro studies were done on a panel of prostate cancer cell lines to understand the molecular basis of combination therapy, and we found that the combination was more effective in the inhibition of cell viability and induction of apoptosis in LNCaP and C4-2b cells (androgen receptor positive) but not in PC-3 cells. " 06/01/1996 - "A noninvasive method for detecting and quantifying androgen receptors (AR) in metastatic prostate cancer may be helpful in choosing the method of treatment and in better understanding the pathophysiology of this disease. " 08/01/1984 - "[A study of correlations between therapeutic efficacy of anti-androgen therapy in prostatic cancer and androgen receptor content of prostatic cancer tissue]" Order ALL the reference details at left...
2.	Neoplasms (Cancer) 07/01/1999 - "In pharmacological studies using rats and other subjects, the product showed excellent affinity with androgen receptors and was found to be anti-androgen active and effective against tumors, and so clinical trials have begun. " 12/01/2004 - "Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor." 11/15/2008 - "These results have implications for the potential study and treatment of various cancers with increased androgen receptor levels." 11/01/2005 - "Further mechanism dissection studies suggested that the tumor suppressor function of TAP was via down-regulation of phosphoinositide 3-kinase (PI3K)/Akt signaling, but not by modulating cell cycle arrest or androgen receptor signaling. " 07/01/2005 - "A study of a well-designed androgen-mustard conjugate provides evidence supporting a novel mechanism for its selective toxicity in androgen-receptor-positive cancer cells. " Order ALL the reference details at left...
3.	Muscular Atrophy (Muscle Atrophy) 03/01/2001 - "Conversely, enhancement of chaperone activity may be beneficial in disorders of protein misfolding, as in the case of androgen receptor aggregates found in Spinal and Bulbar Muscular Atrophy." 05/09/2007 - "CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model." 03/01/2007 - "ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor." 11/01/1996 - "[Study of androgen receptor expression and neuronal vulnerability in X-linked spinal and bulbar muscular atrophy]" 02/01/1995 - "To study the stability of a trinucleotide repeat and to develop an animal model of one of these disorders, spinal and bulbar muscular atrophy (SBMA), we have generated transgenic mice carrying either the normal or expanded repeat human androgen receptor (AR) gene. " Order ALL the reference details at left...
4.	Breast Neoplasms (Breast Cancer) 12/15/1989 - "Improved measurement of androgen receptors in human breast cancer." 06/01/2008 - "Recent studies have identified novel subgroups in ER-negative breast cancer based on the expression pattern of androgen receptor (AR). " 11/01/2006 - "While several studies investigated the association between the androgen receptor (AR) gene, CAG repeat and breast cancer, for the CA and TA repeats in the ER genes there are considerably fewer studies (one for CA and none for TA). " 07/01/2006 - "The purpose of this study was to investigate the influence of androgen receptor (AR) expression in tumour tissue on survival of patients with metastatic breast cancer. " 12/01/2005 - "Several previous studies have found the CAG repeat polymorphism in exon 1 of the androgen receptor (AR) gene to be associated with breast cancer risk among some groups of Caucasian and Asian women. " Order ALL the reference details at left...
5.	Hirsutism 10/20/2007 - "--Hirsutism in women with PCOS, or without measurable changes in plasma androgen levels, can be treated with drugs either inhibiting ovarian or adrenal androgen production, blocking androgen receptors or inhibiting 5alpha-reductase in the hair follicle. " 07/01/2006 - "Consistently, drugs inhibiting androgen receptor binding not only are an effective tool in hirsutism treatment but also show favorable effects on body composition and metabolic features of these women." 03/01/2006 - "In patients with idiopathic hirsutism, a preferential methylation of the of shorter androgen receptor (AR) alleles was hypothesized to be responsible for the abnormal hair growth. " 04/01/2000 - "The role of the CAG repeat polymorphism in the androgen receptor gene and of skewed X-chromosome inactivation, in the pathogenesis of hirsutism." 03/01/1999 - "Idiopathic hirsutism may result from an increase in the androgen receptor (AR)-mediated sensitivity of the hair follicle. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Hormones
2.	Estrogens (Estrogen)
3.	Flutamide (Eulexin)
4.	Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)
5.	Cyproterone Acetate
6.	DNA (Deoxyribonucleic Acid)
7.	Androgen Receptors (Androgen Receptor)
8.	Proteins (Proteins, Gene)
9.	polyglutamine
10.	Testosterone (Sustanon)

Related Therapies and Procedures

1.	Castration
2.	Drug Therapy (Chemotherapy)
3.	Resuscitation
4.	Hair Removal (Depilation)
5.	Prostatectomy (Retropubic Prostatectomy)

Best Treatments:
Research Summary Report
on Prostatic Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1684 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>